Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 Jan;29(1):137-146.
doi: 10.1016/j.euroneuro.2018.10.007. Epub 2018 Nov 6.

The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders

Affiliations

The effect of body mass index on glucagon-like peptide receptor gene expression in the post mortem brain from individuals with mood and psychotic disorders

Rodrigo B Mansur et al. Eur Neuropsychopharmacol. 2019 Jan.

Abstract

There is an increasing interest in the putative role of glucagon-like peptide 1 receptor (GLP-1R) agonists as novel therapeutic agents for mental disorders. Herein, we investigated the expressions of GLP-1R and GLP-2R genes, and its relationship with body mass index (BMI), in the post-mortem brain tissue of patients with mood (MD) and psychotic disorders. Brain samples were localized to the dorsolateral prefrontal cortex (dlPFC) (n = 459) and hippocampus (n = 378). After adjustment for age, sex, ethnicity, post-mortem interval (PMI) and BMI, we observed significant differences, between healthy controls and MD subjects, in GLP-1R and GLP-2R gene expression in the dlPFC (β = 1.504, p = 0.004; and β = 1.305, p = 0.011, respectively); whereas in the hippocampus, only GLP-1R expression was significantly associated with MD (β = -1.28, p = 0.029). No significant differences were found in relation to schizophrenia. In addition, we observed a moderating effect of MD diagnosis on the associations between BMI, GLP-1R and GLP-2R expression values in the dlPFC (β = -0.05, p = 0.003; and β = -0.04, p = 0.004, respectively). There was a similar moderating effect for GLP-1R in the hippocampus (β = 0.043, 95% CI 0.003; 0.08 p = 0.03), but in an opposite direction than observed in the dlPFC. This is the first evidence of abnormal gene expression of GLP-1R and GLP-2R in postmortem brain of individuals with MD, providing a rationale for further inquiry and proof of principle interventional studies.

Trial registration: ClinicalTrials.gov NCT00001260.

Keywords: GLP-1R; GLP-2R; Gene expression; Mood disorders; Obesity; Schizophrenia.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest

The authors declare no conflict of interest related to this work.

Figures

Figure 1–
Figure 1–
Associations between body mass index and (A) GLP-1R and (B) GLP-2R gene expression, according to diagnosis, in the dorsolateral prefrontal cortex. HC: healthy controls; SCZ: schizophrenia; MD: mood disorders.
Figure 2–
Figure 2–
Associations between body mass index and (A) GLP-1R and (B) GLP-2R gene expression, according to diagnosis, in the hippocampus. HC: healthy controls; SCZ: schizophrenia; MD: mood disorders

Similar articles

Cited by

References

    1. Amare AT, Schubert KO, Klingler-Hoffmann M, Cohen-Woods S, Baune BT, 2017. The genetic overlap between mood disorders and cardiometabolic diseases: a systematic review of genome wide and candidate gene studies. Transl Psychiatry 7, e1007. - PMC - PubMed
    1. Baldassano S, Amato A, Mule F, 2016. Influence of glucagon-like peptide 2 on energy homeostasis. Peptides 86, 1–5. - PubMed
    1. Bertilsson G, Patrone C, Zachrisson O, Andersson A, Dannaeus K, Heidrich J, Kortesmaa J, Mercer A, Nielsen E, Ronnholm H, Wikstrom L, 2008. Peptide hormone exendin-4 stimulates subventricular zone neurogenesis in the adult rodent brain and induces recovery in an animal model of Parkinson’s disease. J Neurosci Res 86, 326–338. - PubMed
    1. Brietzke E, Kapczinski F, Grassi-Oliveira R, Grande I, Vieta E, McIntyre RS, 2011. Insulin dysfunction and allostatic load in bipolar disorder. Expert Rev Neurother 11, 1017–1028. - PubMed
    1. Calkin CV, Gardner DM, Ransom T, Alda M, 2013. The relationship between bipolar disorder and type 2 diabetes: more than just co-morbid disorders. Ann Med 45, 171–181. - PubMed

Publication types

MeSH terms

Substances

Associated data